Beyond BCMA: the next wave of CAR T cell therapy in multiple myeloma
Chimeric antigen receptor (CAR) T cell therapy has transformed the treatment landscape of
relapsed/refractory multiple myeloma. The current Food and Drug Administration approved …
relapsed/refractory multiple myeloma. The current Food and Drug Administration approved …
Are we there yet? CAR‐T therapy in multiple myeloma
E Mirvis, R Benjamin - British Journal of Haematology, 2024 - Wiley Online Library
The last few years have seen a revolution in cellular immunotherapies for multiple myeloma
(MM) with novel antigen targets. The principle new target is B‐cell maturation antigen …
(MM) with novel antigen targets. The principle new target is B‐cell maturation antigen …